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Strengths and limitations of this study
 ► The effect of intravenous vitamin C, vitamin B1 or 
glucocorticoid therapy and that of the combination 
therapy on clinically important outcomes will be as-
sessed in this systematic review (SR).
 ► Network meta- analysis (NMA) will address which 
component(s) of the combination therapy contrib-
utes the most to the effect.
 ► The limitations of primary studies will be addressed 
with the framework of Confidence in NetworkMeta- 
Analysis (CINeMA).
 ► The findings from this SR with NMA has the potential 
to inform future clinical trials.
AbStrACt
Introduction Vasoplegia is common and associated 
with a poor prognosis in patients with sepsis and 
septic shock. Vitamin C therapy in combination with 
vitamin B1 and glucocorticoid, as well as monotherapy 
in various doses, has been investigated as a treatment 
for the vasoplegic state in sepsis, through targeting 
the inflammatory cascade. However, the combination 
effect and the relative contribution of each drug 
have not been well evaluated. Furthermore, the best 
combination between the three agents is currently 
unknown. We are planning a systematic review (SR) 
with network meta- analysis (NMA) to compare the 
different treatments and identify the combination with 
the most favourable effect on survival.
Methods and analysis We will include all 
randomised controlled trials comparing any 
intervention using intravenous vitamin C, vitamin B1 
and/or glucocorticoid with another or with placebo 
in the treatment of sepsis. We are interested in 
comparing the following active interventions. 
Very high- dose vitamin C (≥12 g/day), high- dose 
vitamin C (≥6 g/day), vitamin C (<6 g/day); low- dose 
glucocorticoid (<400 mg/day of hydrocortisone (or 
equivalent)), vitamin B1 and combinations of the 
drugs above. The primary outcome will be all- cause 
mortality at the longest follow- up within 1 year but 
90 days or longer postrandomisation. All relevant 
studies will be sought through database searches 
and trial registries. All reference selection and data 
extraction will be conducted by two independent 
reviewers. We will conduct a random- effects NMA to 
synthesise all evidence for each outcome and obtain 
a comprehensive ranking of all treatments. We will 
use the surface under the cumulative ranking curve 
and the mean ranks to rank the various interventions. 
To differentiate between the effect of combination 
therapies and the effect of a component, we will 
employ a component NMA.
Ethics and dissemination This SR does not require 
ethical approval. We will publish findings from this 
systematic review in a peer- reviewed scientific journal and 
present these at scientific conferences.
PrOSPErO registration number CRD42018103860.
bACkgrOund
Vasoplegia, otherwise called vasodilatory 
shock, is well- recognised in sepsis.1 It is char-
acterised by the reduced vascular tone and 
requires escalating exogenous doses of vaso-
pressors to maintain blood pressure even in 
patients with normal cardiac function. In 
order to counteract vasoplegia, the human 
body synthesises and releases norepineph-
rine, epinephrine, cortisol, vasopressin or 
angiotensin II through stimulation of baro-
receptor and chemoreceptor as well as 
proinflammatory cytokines. The autonomic 
system responds immediately to maintain the 
vascular tone and blood pressure; however, 
when responsiveness to catecholamines is 
altered and autonomic control is impaired, 
the prognosis is poor.2–4
To date, glucocorticoids have undergone 
extensive investigation as an adjuvant treat-
ment to restore vascular responsiveness to 
vasopressors,5 and recent large randomised 
controlled trials have reported a reduced 
duration of shock and vasopressor use.6 7
Vitamin C is an essential water- soluble 
vitamin that plays an extensive role as an 
 o
n
 D
ecem
ber 20, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033458 on 12 November 2019. Downloaded from 
2 Fujii T, et al. BMJ Open 2019;9:e033458. doi:10.1136/bmjopen-2019-033458
Open access 
antioxidant, electron donor and cofactor for many 
enzymes and proteins in the human body. It suppresses 
activation of nuclear factor kappa- B8 9; a potent proin-
flammatory mediator which contributes to endothelial 
dysfunction, activation of coagulation and the cellular 
injury characteristic of sepsis through increased transcrip-
tion of multiple proinflammatory cytokines.
Vitamin B1 (thiamine) works as an essential cofactor in 
cellular metabolism. In an animal model of septic shock, 
vitamin B1 improved haemodynamic instability irrespec-
tive of the status of vitamin B1 deficiency.
10
Despite having an appealing model of pathogenesis, 
the effectiveness of vitamin C or vitamin B1 adminis-
tration in sepsis is yet to be determined. Recently, the 
combination of high- dose vitamin C (6 g/day), vitamin 
B1 and hydrocortisone was reported to be a possible 
treatment strategy for septic shock.11 This before–after 
study showed a decrease in mortality of patients with 
septic shock after the implementation of the combi-
nation therapy. A number of clinical trials have been 
conducted since this study was published to assess the 
effect of combination therapy.12 13 This combination 
of interventions appears theoretically reasonable as 
the three drugs share the same cell signalling pathway 
or metabolic cascade.14 To date, at least seven system-
atic reviews (SRs) have tried to assess the effect of 
vitamin C on sepsis or critical illness with conserva-
tive pair- wise meta- analysis15–21; however, the question 
has become more multidimensional since the evolu-
tion of the triple combination therapy, which cannot 
be addressed with a simple pair- wise analysis. In this 
regard, network meta- analysis (NMA) is proposed as 
a useful tool to synthesise the best available evidence 
where multiple interventions are compared.
Objectives
To assess whether vitamin C, vitamin B1 or glucocorticoid 
is effective in patients with sepsis or septic shock and to 
assess whether their use in combination has a greater 
efficacy than any of the drugs given alone, by comparing 
the effect of different therapeutic regimens on mortality, 
severity of organ dysfunction, duration of vasopressor 
therapy and the intensive care unit (ICU) length of stay 
in patients with sepsis or septic shock.
MEthOdS
Study design
We will perform a SR and NMA, using the guidelines 
from the Cochrane Collaboration and Centre for Reviews 
and Dissemination. The protocol is hereby reported 
according to the Preferred Reporting Items for System-
atic Review and Meta- Analysis Protocols guideline22 
(online supplementary file), and the result of the SR will 
be reported according to the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses extension for 
NMA.23
Criteria for considering studies for this review
Types of studies
We will include all randomised controlled trials (RCTs) 
reported as comparing any intervention using vitamin C, 
vitamin B1 and/or glucocorticoid with another or with 
placebo in the treatment of sepsis or septic shock. We will 
include vitamin C, vitamin B1 or glucocorticoid studies 
only if the study drug was given intravenously. We will 
include cluster- randomised trials. Cross- over trials will be 
excluded because of the rapidly evolving nature of sepsis 
or septic shock. Quasi- randomised trials (such as alter-
nating patients) will be excluded, as such methodology is 
well- established as a source of bias.24
Types of participants
Patients with sepsis or septic shock aged 18 years or older 
will be included. Studies that included a minority (<10%) 
of patients under 18 years, or studies with a median or 
mean age of patients over 20 years will be included. Sepsis 
will be defined as reported by the original investigators. 
Septic shock will be defined by the presence of hypoten-
sion requiring vasopressor support in patients with sepsis.
Types of interventions
We are interested in comparing the following active 
interventions: very high- dose vitamin C (≥12 g/day, VHD- 
vitC); high- dose vitamin C (≥6 g/day, HD- vitC); vitamin 
C (<6 g/day, vitC); low- dose glucocorticoid (<400 mg/day 
of hydrocortisone (or equivalent), GC); vitamin B1 (any 
dose, vitB1); and any combinations of the drugs above; 
regardless of the duration. Where the doses were deter-
mined in the unit of mg/kg, then we will use following 
thresholds: ≥150 mg/kg/day for VHD- vitC; ≥75 mg/kg/
day for HD- vitC; <75 mg/kg/day for vitC; and <5 mg/
kg/day of hydrocortisone for GC. We will include inter-
ventions using corticosteroids containing mineralocorti-
coids. Such interventions will be classified according to 
the amount of glucocorticoid contained. We will exclude 
those arms that assessed oral or enteral administration of 
these drugs. We will include either arm of head- to- head 
or placebo (PBO) controlled trials; thus, the synthesis 
comparator set consists of all the interventions listed 
above and placebo- controlled trials. Figure 1 shows the 
network of all possible pairwise comparisons between the 
eligible interventions. We assume any patient who meets 
the inclusion criteria is, in principle, equally likely to be 
randomised to any of the interventions in the synthesis 
comparator set, which means we can imagine a mega- trial 
with all treatments in the network being compared.
Types of outcome measures
We will estimate the relative ranking of the competing 
interventions according to the primary outcome. The 
primary outcome will be all- cause mortality at the longest 
follow- up within 1 year but 90 days or longer after rando-
misation. Secondary outcomes are the severity of organ 
dysfunction over 72 hours measured by the sequential 
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Figure 1 The network structure for all possible pair- wise 
comparisons.
organ failure assessment score or similar scores, time to 
cessation of vasopressor therapy and ICU length of stay.
Search methods for identification of studies
Searches for published RCTs will be undertaken in the 
following electronic databases: Ovid MEDLINE and Epub 
Ahead of Print, In- Process & Other Non- Indexed Cita-
tions, Daily and Versions, Embase Classic+Embase and 
Cochrane Central Register of Controlled Trials. We will 
also screen previously published meta- analyses for rele-
vant citations. Supplement presents the search term used 
in the databases. The electronic search will be supple-
mented with searches for published, unpublished and 
ongoing studies in  ClinicalTrials. gov and WHO- ICTRP 
(online supplementary file). We will ask the identified 
authors as well as experts in the field for any additional, 
unpublished trials.
data collection and analysis
Selection of studies and data extraction
Two authors will independently review references 
and abstracts retrieved by the search and code them 
as ‘retrieve’ or ‘do not retrieve’. We will obtain the 
full texts of the retrieved references and use the same 
criteria to determine which to include or to exclude. 
We will resolve any disagreement through discussion 
or, if required, we will consult a third member of the 
review team. Two reviewers will extract data from the 
included studies independently using a standardised 
data extraction form for study characteristics, outcome 
data and quality rating.
Outcome data
For the primary outcome, we will extract the number of 
patients who were randomised and of these, the number 
who were deceased at the longest follow- up within 1 year, 
but 90 days or longer after randomisation.
For the secondary outcome data, we will extract means, 
SDs and the number of patients randomised in each study 
arm. When means and their SDs are unavailable, we will 
contact study authors to provide the data. When SEs, t- sta-
tistics or p values are reported, these will be transformed 
to SDs. If neither of the above- mentioned measures are 
reported in the original report or a previous SR, the mean 
value of known SDs will be calculated from the group of 
included studies.25 The unit of organ dysfunction scores 
to be used in the included studies can be different, thus 
we will calculate the standardised mean difference (SMD) 
to pool these data. As SMD is difficult to interpret, we 
will use the ratio of means for time to cessation of vaso-
pressor therapy, and ICU length of stay in the sensitivity 
analysis.26 27
If organ dysfunction scores at 72- hour postrando-
misation were not reported, we will extract the score 
at 96- hour postrandomisation. If the score at 96 hours 
was not reported, then we will use the score 48- hour 
postrandomisation.
Missing outcome data
Missing outcome data are sometimes imputed in the orig-
inal trial report. The appropriateness of the imputation 
method will be considered in the risk of bias assessment. 
Participants with missing outcome data will be excluded 
from the analysis.
Data on potential effect modifiers
From each included study, we will extract data on the 
following: study intervention and population character-
istics that may act as effect modifiers: industrial sponsor-
ship, blinding of the personnel, vasopressor dependency 
of the study population.
Assessment of risk of bias in included studies
Two independent authors will assess the risk of bias with 
regard to the primary outcome of this review in the 
included studies using the RoB V.1.0 tool described in 
the Cochrane Collaboration Handbook as a reference 
guide.28 Any disagreement will be resolved through discus-
sion, or discussed with a third author, if necessary. We will 
evaluate the risk of bias in the following domains: gener-
ation of allocation sequence, allocation concealment, 
blinding of study personnel and participants, blinding of 
outcome assessor, attrition, selective outcome reporting 
and other domains (industrial sponsorship, fixed- size 
block randomisation in an unblinded study, baseline 
imbalance, inappropriate study deviation or cointerven-
tion, fraud). Where inadequate details regarding these 
characteristics of the trials are provided in the publica-
tions, we will contact the trial authors in order to obtain 
further information. Risk of bias in each study will be clas-
sified as follows:
1. Low risk of bias: none of the domains is rated as high 
risk of bias and allocation concealment was rated as 
low risk of bias, and three or less were rated as unclear 
risk.
2. Moderate risk of bias: one was rated as high risk of bias, 
but allocation concealment was rated as low risk of bias 
and three or less were rated as unclear risk.
3. High risk of bias: all other cases.
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data synthesis
Characteristics of included studies and information flow in the 
network
We will generate descriptive statistics for each trial, and 
study population characteristics across all eligible trials, 
describing the types of comparisons and clinical or meth-
odological variables such as year of publication, age, 
sepsis or septic shock, organ dysfunction score, severity 
of critical illness, sponsorship and country. The available 
evidence will be presented in the network graph. The size 
of the nodes will show the total number of patients accu-
mulated for each treatment, the breadth of the edges will 
be weighted according to the inverse of the variance of 
the direct summary effect, and the colour of each edge 
will represent risk of bias (low, moderate or high).
Measures of treatment effect
Relative treatment effects
We will estimate the pairwise relative treatment effects of 
the competing interventions using OR for dichotomous 
outcomes and mean difference (MD) or SMD for contin-
uous outcomes. We chose the OR because the calculations 
to estimate the component- specific effects in component 
NMA are dependent on the mathematical features of the 
OR; in turn, the risk ratio (RR) is not suitable because 
it lacks symmetry. Furthermore, a methodological study 
has found possible bias in Cochrane random- effects meta- 
analysis using RR due to the restricted range of RR.29 
Results from the NMA will be presented as summary rela-
tive effect sizes for each possible pair of treatments.
Assessment of transitivity across treatment comparisons and NMA
Transitivity is a key assumption of NMA, and it can be 
seen as an extension of the clinical and methodological 
heterogeneity across comparisons. We will investigate the 
distribution of the possible effect modifiers mentioned 
above across treatment comparisons carefully. We assume 
that patients who fulfil the inclusion criteria for studies 
considered for this SR are potentially eligible for any of 
the interventions that we plan to compare. If the included 
studies are sufficiently similar with respect to the distribu-
tion of the effect modifiers, we will conduct a random- 
effects NMA to synthesise all evidence for each outcome 
and obtain a comprehensive ranking of all interventions. 
We will assume a single heterogeneity parameter for each 
network. We will present the summary ORs or (S)MD for 
all pairwise comparisons in a league table. We will also 
estimate the prediction intervals to assess how much the 
common heterogeneity affects the relative effect with 
respect to the extra uncertainty anticipated in a future 
study. We will compare the tau- squared with their empir-
ical distributions.30 31 We will obtain a treatment hierarchy 
using the surface under the cumulative ranking curve 
(SUCRA) and mean ranks. SUCRA can also be expressed 
as a percentage interpreted as the percentage of the effi-
cacy of a treatment that would be ranked first without 
uncertainty.32
Component NMA
We will also employ a component NMA model, which 
is an extension of the standard NMA model.33 We will 
differentiate between the effect of a component and the 
effect of combination therapies. We will assume addi-
tivity of component effects, that is, the total effect of 
each combination of interventions is assumed equal to 
the sum of effects of the included components. In this 
model, adding a component c to a composite interven-
tion X will lead to an increase (or decrease) of the odds 
of the event or (S)MD by an amount only dependent on c, 
not on X. Then the component- specific incremental OR 
will be denoted by  iORc , where  iORc = OR(X+c)vs(X) . A large 
 iORc  suggests that component c has a large impact on the 
outcome. Then the estimation of ORs between any two 
composite interventions will be calculated by combining 
the component- specific incremental ORs.34 For example, 
 OR(HD−vitC+GC)vs(vitC+vitB1) = (iORHD−vitC × iORGC) / (iORvitC × iORvitB1) ·  As 
the calculations are dependent on the mathematical 
features of the OR, we will report the result as the OR.
Assessment of inconsistency
The evaluation of transitivity will be supplemented with 
an evaluation of consistency with the statistical agree-
ment between direct and indirect evidence. We will use 
local as well as global methods to evaluate consistency.35 
We will use a side- splitting approach to evaluate inconsis-
tency within each pair- wise comparison as a local method 
and the design- by- treatment model as a global method to 
detect inconsistency in the network.
Sensitivity analysis
We will perform the following sensitivity analyses to eval-
uate the robustness of our findings.
1. Analysing only studies with low risk of bias.
2. All- cause mortality at the longest follow- up.
3. Analysing only studies published in 2010 or after.
4. Analysing time to cessation of vasopressor therapy and 
ICU length of stay as the ratio of means.
We will perform NMA in R V.3.5.1 using the netmeta 
package.36
Assessment of confidence in network estimates
We will assess the confidence of the network estimates of 
the primary outcomes using the CINeMA framework,37 
which characterises the confidence of a body of evidence 
on the basis of within- study bias, across- studies bias, 
imprecision, heterogeneity and inconsistency. We will use 
a web application CINeMA.38
Ethics and dissemination
This review does not require ethical approval. We will 
publish findings from this SR in a peer- reviewed scientific 
journal and present these at scientific conferences. Also, 
the findings will be disseminated through media where 
appropriate with layperson language for the purpose of 
knowledge translation. The dataset will be locked when 
the The VitamInC, hydrocorTisone and thiAMINe in 
patients with Septic shock (VITAMINS) trial completes 
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The dataset will be made available based on a reasonable 
request to the researchers.
Patient and public involvement
There was no patient or public involvement in the devel-
opment of this manuscript.
Limitations
We acknowledge several limitations of the proposed 
review. First, as we plan to do meta- analysis using aggre-
gated data, we can only classify study arms of vitamin C 
into three groups, that is, VHD- vit C, HD- vit C and vit- C, 
according to the dosage as reported by the investigators. If 
a fixed dose, that is, g/day, was used in a trial, the effect of 
the intravenous vitamin C might be different in patients 
with various weights. Second, we compare multiple inter-
ventions in this SR which might be likely to find statistical 
significance solely by chance. As there are no formal and 
satisfactory methods to account for the multiplicity in SR, 
the results should be cautiously interpreted.
Conclusions
In this SR and NMA, we will assess the effect of intrave-
nous vitamin C, vitamin B1 or glucocorticoid therapy and 
that of the combination therapy on mortality, the severity 
of organ dysfunction, the length of vasopressor therapy 
and ICU length of stay in patients with sepsis. The NMA 
will also address which component(s) of the combination 
therapy would contribute the most to the effect.
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